Quanterix Is A Finalist For The 2014 Red Herring Top 100 North America Award
Lexington – (Business Wire) – May 5, 2014 Quanterix, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that it has been selected as a finalist for Red Herring’s Top 100 North America award, a prestigious list honoring the year’s most promising private technology ventures from the North American business region.
Red Herring has been selecting the most exciting and promising start-ups and “scale ups” since 1995. Finalists are still evaluated individually from a large pool of hundreds of candidates based across North America. Twenty major criteria underlie the scoring and process, including technological innovation, management strength, market size, investor record, customer acquisition and financial health. The list of finalists often includes the best performing and prominent companies of that year. “The finalists list confirms the excellent choices made by entrepreneurs and VCs and the start-ups’ solid roots in corporate America, embracing their innovations. By all metrics, it emphasizes the United States’ entrepreneurial excellence,” said Alex Vieux, publisher and CEO of Red Herring.
“This recognition further validates the remarkable Simoa technology that the team at Quanterix has developed, which is now available to researchers around the world,” said Paul Chapman, President and CEO at Quanterix. “With Simoa, it is now possible to count individual protein molecules, allowing truly novel research to be conducted in a number of areas, including Alzheimer’s disease, traumatic brain injury, HIV, oncology and many other applications that will drive the diagnostics and therapies of tomorrow. We are honored that Red Herring has recognized the importance and potential benefit for human health of Quanterix’ Simoa technology.”
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com/simoa-is-here.
Nikki Festa & Caitlyn Keating
Share this page